Assessment of AI Prediction Models in Prediction of Acute Kidney Injury in Critical Patients
Launched by ASSIUT UNIVERSITY · Feb 26, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well artificial intelligence (AI) can predict acute kidney injury (AKI) in critically ill patients who are being treated in the intensive care unit (ICU). The goal is to see if AI can identify signs of kidney problems before they become serious, allowing doctors to take action early and potentially improve patient outcomes.
To participate in this study, you must be an adult aged 18 or older who is admitted to the ICU. Unfortunately, patients who are under 18, have severe kidney disease, already have AKI when they arrive at the ICU, or cannot provide enough medical information will not be eligible. If you join the trial, you’ll help researchers understand how AI can be used in hospitals to enhance care for patients at risk of kidney injuries. The study is currently not recruiting participants, meaning it has not started yet, but it aims to make a difference in critical care treatment in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All adult (aged 18 years old and older) patients who were admitted to the ICU were included in this study.
- Exclusion Criteria:
- • • patients under 18 years old
- • End-stage renal disease
- • Acute Kidney Injury at ICU admission
- • Inability to obtain sufficient clinical data
About Assiut University
Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Alaa El-Dein ElMoneim Sayed, professor
Study Director
Assiut University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported